Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32639 TG THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorp ...

TG Therapeutics Inc TGTX on Monday reported first-quarter earnings per share of 3 cents, a shift from a loss of 7 cents a year ago, but below the consensus of 17 cents.The company reported sales of $120.86 million, up from $63.47 million a year ago, beating the consensus of $118.43 million.Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, stated, “2025 is off to a strong start, and I’m incredibly proud of the progress made thus far. Our performance in the first quarter, including BRIUMVI ...

A near-doubling of revenue and a flip into profitability on the bottom line apparently weren't good enough for TG Therapeutics (TGTX -11.39%) shareholders on Monday.The company, best known for its multiple sclerosis (MS) drug Briumvi, posted its first-quarter results that morning, and investors expressed their displeasure by trading out of the stock aggressively. In midafternoon action its price was down by more than 14%, comparing most unfavorably to the 0.2% dip of the S&P 500 index at that point.Sales bo ...

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.TG Therapeutics, Inc. (NASDAQ: TGTX ), the Morrisville, North Carolina-based commercial stage Pharma company that markets and sells Briumvi (ublituximab), approved in the U ...

TG Therapeutics (TGTX) came out with quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.18 per share. This compares to loss of $0.07 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -83.33%. A quarter ago, it was expected that this biopharmaceutical company would post earnings of $0.08 per share when it actually produced earnings of $0.15, delivering a surprise of 87.50%.Over the last four quarter ...

TG Therapeutics (TGTX) Q1 2025 Earnings Call May 05, 2025 08:30 AM ET Speaker0 Greetings, and welcome to TG Therapeutics First Quarter Conference Call and Webcast. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Jenna Bosco, Chief Communications Officer. Thank you. You may begin. Speaker1 Thank you. Welcome, everyone, and thanks for join ...

Conference call to be held today, Monday, May 5, 2025, at 8:30 AM ET New York, NY, (May 5, 2025) – TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results for the first quarter of 2025, along with recent company developments and provided an update on 2025 revenue guidance. Michael S. Weiss, the Company's Chairman and Chief Executive Officer, stated, "2025 is off to a strong start, and I'm incredibly proud of the progress made thus far. Our performance in t ...

First quarter 2025 BRIUMVI U.S. net revenue of $119.7 million Raises full year 2025 global net revenue target to approximately $575 million and raises full year BRIUMVI U.S. net revenue target to approximately $560 million Conference call to be held today, Monday, May 5, 2025, at 8:30 AM ET NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results for the first quarter of 2025, along with recent company developmen ...

Conference call to be held Monday, May 5, 2025, at 8:30 AM ETNEW YORK, April 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, May 5, 2025, at 8:30 AM ET to discuss results for the first quarter of 2025 and provide a business outlook for the remainder of 2025. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call. In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 ...

文章核心观点 - TG Therapeutics股票在过去三个月上涨29.5%，而行业下跌11.2%，Briumvi销售超预期及管线进展推动股价，公司目前Zacks Rank为3（持有） [1][8][9] 公司股价表现 - 过去三个月TG Therapeutics股票上涨29.5%，行业下跌11.2% [1] Briumvi销售情况 - 2022年12月Briumvi获FDA批准治疗复发型多发性硬化症成人患者，2024年销售超管理层预期 [1] - 近几个季度Briumvi受患者欢迎趋势有望在2025年延续，2024年净产品销售额3.137亿美元，2023年为9200万美元 [2] Briumvi相关进展 - 2025年公司预计全球收入约5.4亿美元，其中美国Briumvi净产品收入近5.25亿美元 [3] - 公司获美国专利商标局三项Briumvi额外专利，专利保护延至2042年，可防止美国市场仿制药侵蚀销售 [3] - 公司正开发Briumvi自我注射皮下制剂治疗复发型多发性硬化症，去年8月启动一期研究评估皮下Briumvi治疗复发型多发性硬化症患者，也在进行评估皮下Briumvi治疗重症肌无力的一期研究 [4] 其他管线研究 - 2024年1月公司与Precision BioSciences达成许可协议，获其异体CD19 CAR T疗法azer - cel全球权利，用于治疗某些自身免疫性疾病 [7] - 2024年8月FDA批准azer - cel治疗进行性多发性硬化症的新药研究申请，azer - cel治疗进行性多发性硬化症一期研究预计很快开始招募参与者 [7][8] 其他相关公司情况 - Jazz Pharmaceuticals目前Zacks Rank为2（买入），过去60天2025年每股收益预期从22.11美元增至23.33美元，2026年从23.23美元增至23.35美元，年初至今股价下跌10.6%，过去四个季度三次盈利超预期，平均惊喜率3.20% [9][10] - Krystal Biotech目前Zacks Rank为2（买入），过去60天2025年每股收益预期从5.40美元增至7.00美元，2026年从9.15美元增至10.84美元，年初至今股价上涨7.4%，过去四个季度三次盈利超预期，平均惊喜率3.29% [9][11]